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Objectives: To evaluate the views of Australian pharmacists on expanded pharmacist 
prescribing roles and identify important drivers and barriers to its implementation.  
Setting: Pharmacists in Australia 
Method: Data were collected using a self-administered questionnaire distributed nationally to 
a random sample of pharmacists either directly, or in the case of one state, via community 
pharmacies. One-way ANOVA and Chi-square testing were used to identify significant 
associations. Factor analysis was conducted to pool variables and the derived factors were 
subjected to regression analysis.  
Main Outcome Measures: Perceptions of Australian pharmacists on expanded prescribing 
and the relationships between variables derived.  
Results: A total of 2592 questionnaires were distributed and a response rate of 40.4% was 
achieved (n=1049). Of the respondents 83.9% strongly agreed/agreed to an expanded 
prescribing role for pharmacists and 97.1% reported they would need further training. Of the 
respondents 896 agreed that pharmacists should engage in supplementary, independent 
prescribing or both. Of these 69.1% preferred only supplementary prescribing, 3.3% 
independent prescribing and 27.4% both models.  Both models were found to be positive 
predictors of expanding pharmaceutical services through prescribing (p<0.001) with 
supplementary prescribing showing a stronger association (β=0.52 vs. β=0.18). Pharmacists’ 
opinion based on their current perceptions of their clients was an important predictor in 
expanding pharmaceutical services through prescribing (p=0.005). Inadequate training in 
patient assessment, diagnosis and monitoring were the strongest barriers to expanded 
pharmacist prescribing (p<0.001).   
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Conclusions: The majority of Australian pharmacists supported an expanded pharmacist 
prescribing role. Support for supplementary was stronger than independent prescribing. 
Pharmacists acknowledged that they would need further training to perform such roles. 
 
Impact of findings on practice 
 
• Australian pharmacists appreciate an expanded pharmacist prescribing role. 
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Expanded prescribing as a specialist role for pharmacists is developing in several countries. 
In the United Kingdom (UK) a supplementary prescribing model including pharmacists has 
recently been expanded where, within specific criteria, pharmacists may prescribe 
independently.1,2 In the United States of America (USA) pharmacists are involved with 
doctors in collaborative drug therapy management.3 Major developments in pharmacist 
prescribing have also occurred in Canada, where Alberta implemented a three category 
prescribing model: ‘adapting a prescription’, emergency prescribing, and  initiating and 
managing drug therapy.4,5 Van Foppe et al. have suggested that the pharmacy profession in 
Europe, other than in the UK, was not at a stage where pharmacist prescribing could be 
implemented.6,7   
 
In supplementary prescribing the primary prescriber diagnoses and initiates therapy whilst the 
supplementary prescriber continues the prescribing within the agreed management plan 
parameters.2,8 In the case where pharmacists prescribe independently of medical practitioners, 
they assume the responsibility for clinical assessment of the patient, establishing the 
diagnosis and clinical management for a defined range of conditions within professional and 
clinical competence.2,9  
              
Qualified pharmacist independent prescribers in the UK are able to prescribe any licensed 
medicine within their area of expertise except for controlled drugs.1,2 The restriction on 
prescribing of controlled drugs is due to change pending the amendment of legislation. 10 
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Pharmacists in Australia are able to prescribe medications listed under ‘Pharmacy medicines’ 
(S2) and ‘Pharmacist only medicines’ (S3) schedules. These medicines are available to the 
public from community pharmacies. Some drugs in these categories have been “down-
scheduled” from “prescription only” medicines. Australian pharmacists are also able to 
continue the supply of prescription only medications based on ‘emergency supply’ and 
‘repeat prescription’ systems. 
  
The Australian Government Productivity Commission has recommended that Australia 
should expand the roles of other health professionals to include some current aspects of 
doctor’s tasks.11 The Australian Medical Association (AMA) does not consider the 
Productivity Commission’s recommendation as the best solution for addressing workforce 
shortages, however, the medical profession embraces the idea of allocating clinical 
responsibilities to other medically trained health professionals “wherever it can be done 
safely and effectively”.12  The AMA at the same time has warned that this could lead to 
shortages of other healthcare professionals. In terms of expanding pharmacist prescribing 
specifically, the AMA has in the past signalled that it does not support such a role for 
pharmacists.13 The Royal Australasian College of Physicians (RACP) supports task transfer 
“both across its specialty groups and to other health professionals as long as this transfer is 
“evidence-based, safe, cost-efficient and it facilitates patient care.”14   
 
The aims of this study were to survey Australian pharmacists for their views on 
supplementary and independent prescribing as expanded roles of pharmaceutical professional 
practice and to identify the important drivers and barriers to pharmacist prescribing in 
Australia.               
        




This study was approved by the Human Research Ethics Committee of Curtin University of 
Technology.  
Questionnaire development  
Data were collected using a standardised questionnaire (shown in the “Appendix”). The 
questionnaire was initially constructed based on a review of the relevant literature and findings 
from a focus group meeting. It was then pre-piloted on 114 Western Australian pharmacists, 
following which minor changes were made. The final questionnaire had nine sections related to: 
1) expansion of pharmacy professional services and pharmacist prescribing, 2) pharmacists 
perceptions of their clients, 3) advantages of expanding the pharmacist’s prescribing role 4) 
prescribing models preferred 5) barriers to expanded pharmacist prescribing 6) therapeutic areas 
in which pharmacists supported expanded prescribing 7) training requirements to prescribe 8) 
infrastructural implications, and 9) expansion of the current role in the management of minor 
ailments. Dependent upon the question, pharmacists were either asked to respond yes/no or to 
complete a five point Likert scale to assess their level of agreement with a particular statement.   
The questionnaire also contained a section gathering some basic demographic data.   
The self-administered questionnaire was posted nationally to a random sample of pharmacists 
either directly or in the state of New South Wales (NSW) through a random sample of 
community pharmacies. The sample was drawn from Registers obtained from State Pharmacy 
Boards (South Australia, Victoria, Tasmania) and the Pharmaceutical Council of Western 
Australia. Registers for NSW and Queensland were not made available due to privacy issues.  
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A random sample of pharmacies in NSW was chosen from those listed in the telephone directory 
“Yellow Pages”. The sample for Queensland was drawn from the list of pharmacists made 
available publicly online by the Pharmacy Board of Queensland. A 20% sample was drawn for 
each of the abovementioned States using an electronic randomiser. The Northern Territory (NT) 
and the Australian Capital Territory (ACT) were excluded due to limited numbers of potential 
respondents. The questionnaires were distributed by mail in December 2007 and a follow-up in 
January 2008 and included “replied paid” envelopes.  
 
Data analysis  
Data were coded and analysed using SPSS v16.  Standard descriptive statistics were used to 
summarise demographic data and responses to the questionnaires (frequencies for categorical 
variables, and means and standard deviations for variables measured on a continuous scale).  
Comparisons of binary (Yes/No) variables across different geographical areas and across 
different practice settings were performed using Chi-square statistics.  Variables measured on the 
Likert scale were either formed into 3 categories (agree, neutral, disagree), or treated as 
continuous variables.  With the large sample size used in this study, the distribution of the mean 
score for variables based on the Likert scale can safely be assumed to be Normal (Central Limit 
Theorem).  Analysis of Variance (ANOVA) was used to compare the means of Likert scale 
variables where the independent variables had more than 2 categories.  For example, the 
influence of years since the Pharmacist’s registration (divided into 4 groups: 0-5 years, 6-10 
years, 11-20 years and >20 years) on attitudes measured on the Likert scale was analysed using 
ANOVA.   
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On the questionnaire, sections: 1 (“Prescribing and the future of the pharmacy profession”), 2 
(“Pharmacists opinions on how expanded prescribing would be received by clients”), 3 
(“Pharmacists’ opinions towards potential advantages of expanded prescribing”), and 5 (“Barriers 
to expanded prescribing”) each contained several questions.  Internal consistency of the questions 
within each section was performed using Cronbach’s coefficient alpha.  This was done to confirm 
that the questions within each section were measuring different facets of the same theme.  In 
order to reduce each section to a single “score” to represent each theme, responses could have 
been summed within each section (giving equal weight to each question).  Factor Analysis is a 
more rigorous method of identifying appropriate question weightings so that the weighted linear 
combination of responses explains as much of the variance for the section as possible.  
Accordingly, Factor Analysis was applied to each of these four sections in turn with the aim of 
obtaining a single summary score for each section for each respondent.  Multiple regression 
analysis was then performed with the Section 1 summary score as dependent variable (renamed: 
“Expanded pharmaceutical services through prescribing”), so that factors associated with this 
variable could be identified. 
 Results  
A total of 1049 of the 2592 questionnaires distributed were returned giving a response rate of 
40.4%. Demographic characteristics of the respondents are summarised in Table 1. The majority 
of the respondents were employee community pharmacists working in larger pharmacies (annual 
income ≥ AU$2M).  
 
[Insert table 1 here]  
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Frequency distributions revealed that 83.9% of respondents reported that pharmacists should have 
access to expanded prescribing rights. Almost all respondents (97.1%) reported that if they were 
to undertake additional prescribing responsibilities, they would need further training. Chi-square 
testing for these findings showed no significant differences between samples drawn from 
different States in relation to the above questions (p=0.095; p=0.293, respectively). The first 2 
questions of section 4 in the questionnaire relate to pharmacists prescribing independently or 
supplementary to a doctor.  The response to each question was reduced to “agree/strongly agree” 
versus other, and respondents were identified as those who supported Supplementary alone, 
Independent alone, both or neither of these prescribing models. Of the 1049 respondents, 896 
agreed to at least one of these models.   Amongst these 896 respondents, supplementary 
prescribing alone was the preferred model (69.1% strongly agreed/agreed) with far fewer 
supporting only an independent model (3.3% strongly agreed/agreed). A total of 246 of 
respondents preferred both models (27.4% strongly agreed/agreed). Most respondents (n=1019, 
74.1%) did not agree that expanded prescribing should be limited only to hospital pharmacists. 
One-way ANOVA showed that there was no significant difference between pharmacists working 
in different settings (i.e. community, hospital, medication reviews, others) in regards to their 
preference for independent (p=0.115), or supplementary prescribing models (p=0.087). No 
significant difference was also found using one-way ANOVA between pharmacists’ period of 
registration and their preference for the above prescribing models (p=0.835; p=0.663, 
respectively).  
Respondents supported an expanded prescribing role as it would better use pharmacists’ skills 
and ease the work-load burden on general medical practitioners. The majority of respondents did 
not regard increased government or patient cost, or reduction in the quality of patient care as 
significant barriers to this role. These attitudes are summarised in Table 2.  
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[Insert table 2 here]  
Respondents who preferred only the supplementary prescribing model, showed strongest support 
for expanded prescribing for asthma and a limited range of infections, followed by hypertension, 
pain management and diabetes. Those that favoured only the independent prescribing model 
showed strongest support for a limited range of infections and pain management. Respondents 
who supported both models showed remarkable preference consistency with those that only 
preferred either supplementary or independent prescribing. These indicated that pharmacists who 
preferred the independent prescribing model showed strongest prescribing support for the areas of 
a limited number of infections and pain management. On the other hand, asthma was the most 
preferred therapeutic area of prescribing for supporters of the supplementary prescribing model, 
regardless of their support for the independent model. Lower levels of support by all groups were 
seen for an expanded role in anticoagulation and heart failure. These preferences are summarised 
in Table 3.  
 
[Insert table 3 here]  
 
Factor Analysis  
Principal Component Analysis was performed on each of sections 1, 2, 3 and 5.  In each case, the 
Kaiser-Meyer-Olkin measure of sampling adequacy was high (>0.6) and Bartlett’s test of 
sphericity (<0.0001) confirmed the suitability of these data for this type of analysis. The 
following factors were extracted for the groups of questions 1, 2, and 3 above: 1) Expanding 
pharmaceutical services through prescribing 2) Pharmacist prescribing drivers 3) Pharmacists’ 
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opinion based upon their perceptions of their clients. Only one factor for each of these questions 
was identified as having a significant contribution to the total variance for these questions 
(eigenvalue greater than one).  For each factor extracted, the percentage of variance explained 
was >58%. Internal consistency using Cronbach’s alpha for these groups of statements were: 1) 
0.86, 2) 0.89 and 3) 0.82. The factor loadings for these three factors were as follows: 1) 
Expanding pharmaceutical services through prescribing: (0.77, 0.93, 0.88, 0.79); 2) 
Pharmacist prescribing drivers: (0.82, 0.83, 0.71, 0.72, 0.75); 3) Pharmacists’ opinion based 
upon their perceptions of their clients: (0.76, 0.82, 0.85, 0.85, 0.77, 0.69, 0.87, 0). These 
loadings correspond with the questions in questionnaire sections 1,2 and 3 and are in the 
same order as these questions.   
In factoring the group of questions in section 5 (barriers to an increased pharmacists’ 
prescribing role), three factors emerged with eigenvalues of more than 1.0. Clearer 
interpretation of the factors was obtained by applying a Varimax rotation as shown in Table 
4. Three factors, which explained 64.3% of the variance pertained to: i) other barriers; ii) 
increased cost and deterioration of patient care and iii) inadequate training in diagnosis, patient 
assessment and monitoring. Cronbach’s alpha internal consistencies were as follows: i) other 
barriers 0.83; ii) increased cost and deterioration of patient care 0.87 and iii) inadequate 
training in diagnosis, patient assessment and monitoring 0.83. Note that the final question for 
this section (“None of the above”) was excluded from this analysis. 
 
[Insert table 4 here]  
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Regression analysis  
Two regression analyses were performed, both of them using the factor summary score obtained 
from section 1 as the dependent variable (“Expanding pharmaceutical professional services”).   
The first examined the data for any association with independent and supplementary prescribing. 
This model explained 36.7% variance. Both independent and supplementary prescribing were 
positive predictors of expanding pharmaceutical services through prescribing (p<0.001). 
Pharmacists who preferred supplementary prescribing showed a stronger association (based on 
the regression coefficient, β) compared to pharmacists who preferred independent prescribing (β 
=0.52 vs. β =0.18).  
In the second regression model, the independent variables included the five summary scores 
found through the factor analyses performed on sections 2,3 and 5.  This model explained 62.2% 
of variance.  The results of this model, shown in Table 5, indicated that both pharmacist 
prescribing drivers (i.e. advantages) and their opinions based upon their experience with clients 
were important positive predictors of an expansion of pharmacist services through prescribing 
(p<0.001 and p=0.005;  β =0.74 and  β =0.12, respectively). The model also showed patient 
diagnosis, assessment and monitoring were more negatively associated with expanding services 
through prescribing as opposed to other barriers (i.e. disadvantages) or increased cost and 
deterioration of patient care (p<0.001, p=0.003 & p=0.004;  β =-0.098,  β =-0.091 &  β = -0.075), 
respectively.  The above findings are summarised in Figure 1, which encapsulates the factors and 
weightings that had significant positive and negative impact on pharmacists considering moving 
towards an expanded prescribing role.  
 
[Insert table 5 here] 
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To our knowledge this is the first major study on the attitudes of Australian pharmacists to 
pharmacist prescribing. This study has examined the views of a large sample of Australian 
pharmacists on pharmacist prescribing from all areas of pharmacy practice and all Australian 
states.  Respondent pharmacists’ place of practice in this study was reflective of the 
Australian Bureau of Statistics (ABS) Population Census data 2006 (i.e. Community 
pharmacists 84.9%, Hospital 11.2% and Industrial 3.8%). 15 A response rate of 40.4%, 
although adequate for a postal survey, leaves a possibility of some non-respondents not 
sharing the same views as respondents. However, the respondents’ highly supportive views 
for expanded pharmacist prescribing (83.9%) suggests that non-respondents’ views would not 
markedly influence the findings.   
 
Pharmacists who participated in this study were clearly in favour of expanding the scope of 
pharmaceutical services through expanding their prescribing role, although they believed 
further training was needed to assume such a role. Australian pharmacists preferred a 
supplementary prescribing model. The current strong support for the supplementary model 
might suggest this model should be initially introduced.  The level of support for independent 
prescribing in this study was less than reported in a previous Australian study.16 However, 
that study was limited by a low response rate (6.4%) and an under-representation of 
community pharmacists. 16 Although in this study both supplementary and independent 
prescribing were positive predictors of expanding pharmaceutical services through 
prescribing, pharmacists who were in favour of supplementary prescribing showed a stronger 
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association towards this expansion. It is worth emphasising that pharmacists’ opinions based 
upon their perceptions of their clients was shown to be an important predictor of expanding 
pharmaceutical services through prescribing. To date there is a lack of literature exploring 
this particular relationship. Respondents who favoured the independent model showed 
support for less therapeutic areas of prescribing compared to supporters of supplementary 
prescribing. This was probably because supplementary prescribing does not involve the initial 
diagnosis and prescribing. 
 
The positive attitude towards a supplementary prescribing model found in this study is 
supported by the views of pharmacists reported elsewhere. A survey conducted in the UK by 
Hobson and Sewell6, suggested that despite concerns, pharmacists had a positive attitude 
towards supplementary prescribing and that pharmacists in the UK wished to assume this 
role. The main reasons for Australian pharmacists supporting an expanded role in prescribing 
were: better use of pharmacists’ skills, easing the burden from overloaded general 
practitioners and pharmacists’ drug knowledge. In several ‘Crown Reports’, a greater use of 
pharmacist skills in order to develop a more flexible system of prescribing, administration 
and supply of medicines was identified as the main driver for expanding pharmacist 
prescribing in the UK. 9,17  In addition, England’s Department of Health identified 
improvement of patient care, medication access and team work within the healthcare system 
as the main aims for introducing independent pharmacist prescribing. 2  
 
The major concerns identified by respondents in this study for expanded pharmacist 
prescribing were inadequate training in patient assessment, diagnosis and monitoring. These 
concerns were also found to be the strongest negative predictors of expanding pharmacists’ 
prescribing role in Australia.  Early experience from supplementary prescribers in the UK has 
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suggested inadequate funding to be a major limitation for delivering this service. 18 Review of 
the literature revealed a variety of other limitations including potential conflict with doctors, 
need for greater liability insurance, excessive workload and time pressures.19-22 A possibility 
for fragmentation of care resulting in increased costs and inefficiencies within the health care 
system has also been reported. 9 Conflict of interest with pharmacists having a commercial 
interest in prescribing with supply and inadequate access to patient records were also reported 
to be obstacles towards the adoption of this role.22,23  
 
The health system in Australia is under stress from factors such as the ageing population, 
increased morbidity, increased chronic diseases and insufficient doctors to keep pace with 
population growth. 24 Insufficient numbers of health professionals is driving task transfer.12 
There are indications that fewer medical graduates are choosing general practice as a career, 
hence adding to the existing general practitioner shortage.25 Furthermore, Joyce et al.26 
predicted a continued shortage of general practitioners in Australia, hence suggesting that 
innovative primary medical care policies were necessary. This needs to be weighed against 
international experience with the established supplementary prescribing model in the UK 
showing benefits for both patients and pharmacists. These benefits have included: improved 
patient management, job satisfaction for pharmacists and greater patient satisfaction. 18 A 
qualitative study conducted in Australia by Bessell et al. 27 proposed four practice models 
where pharmacists could initiate, modify and monitor access and use of prescription 
medicines. According to this study, these models provided consumers with improved, 
responsible and safe access to prescription medicines. Other studies, although limited in 
representativeness also confirmed that an expanded role in prescribing was supported by 
Australian pharmacists. 18,28  
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Results of this study identify strong pharmacist support for constructing policies and 
recommendations towards future pharmacist prescribing in Australia. They are also valuable 
elsewhere, given the global interest on this issue and the lack of literature exploring 







Australian pharmacists strongly supported an expanded pharmacist prescribing role, despite 
perceived barriers. Their preference was for a supplementary over an independent prescribing 
model, with support of this model being a strong predictor of pharmacists expanding their 
pharmaceutical services through prescribing. A significant driver for expanding the 
pharmacist’s prescribing role was the pharmacists’ opinion based on their current perceptions 
of their clients. Important barriers included inadequate skills in patient assessment, diagnosis 
and monitoring. This study provides evidence to regulatory bodies that a move towards an 
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Variable Category n (%) 
Gender Male 536 (51.6) 
Female 503 (48.4) 
Mean age (SD)  42.8 years (SD=13.5) 
Mean years (SD) of registration as 
pharmacist 
 20.5 years (SD=14.2) 
 
Practice setting 
Community 873 (84.1) 
Hospital 119 (11.5) 
Medication reviews (i.e. consultant pharmacists) 14 (1.3) 
Other 32 (3.1) 
Pharmacy ownership  Owners  359 (41.1% of community 
pharmacists) 





Australian places of practice 
Victoria 422 (40.9) 
New South Wales 199 (19.3) 
Queensland 88 (8.5) 
Western Australia 156 (15.1) 
South Australia 121 (11.7) 






a For each category there were some missing responses 
 







































Better use of pharmacists skills 77.9 Inadequate training in disease diagnosis  82.5 
Easing the burden from overloaded GP’s 77.6 Inadequate training in patient assessment and 
monitoring  
70.1 
Pharmacists drug knowledge 73.4 Inadequate facilities within pharmacies 62.2 
Pharmacy profession securing a more important role in 
health care 
69.1 Increased likelihood of litigation  57.9 
Patients’ better access to their medications 67.5 Pharmacists’ lack of time 53.1 
Pharmacists’ highly regarded role by the community 62.2 Commercial interest in both dispensing and 
prescribing  
50.4 
Pharmacists patient assessment skills 48.5 Reduction in the quality of patients care 32.9 
Contribution to increased pharmacy profits 42.8 Potential decrease in quality of current services 
offered by pharmacists 
28.0 
 Increased hospital admissions  24.8 
Increased patient costs 18.3 











    A/SA=Agree/Strongly agree; N=neutral; D/SD=Disagree/Strongly disagree 
a   Missing is from the data set for these questions 
























 Supporters of 
supplementary  model 
only 
 (n=516,  




model only  
(n=28, 2 missing) 
 
Supporters of both supplementary and independents 
prescribing models  
(n=208, 38 missing) 
Independent model Supplementary    model 
























Antibioticsb 79.1 6.4 14.6 82.1 7.1 10.7 78.3 6.6 15.1 75.4 6.3 18.3 
Diabetes 73.4 11.8 14.7 46.4 28.6 25.0 45.1 10.8 44.1 77.9 7.2 14.9 
Hypertension 76.5 8.9 14.5 46.5 10.7 42.8 45.1 12.3 42.7 75.0 9.6 15.4 
Heart Failure 43.5 16.9 39.6 28.6 17.9 53.5 21.1 17.2 61.8 49.7 18.0 32.2 
Asthma  86.6 6.0 7.4 67.9 10.7 21.4 72.0 11.0 17.2 80.8 3.8 15.4 
Anticoagulation 55.6 13.4 31.0 46.4 14.3 39.3 29.4 15.7 54.9 59.3 13.9 26.8 
Pain management 75.9 10.7 13.4 82.1 10.7 7.2 74.0 8.5 17.5 73.2 8.1 18.7 
 
 























 Factors extracted(a) 
Reasons for which pharmacists should not have expanded prescribing rights i ii iii 
Increased confusion amongst the public as to the roles of GP's and pharmacists 0.752   
Pharmacists’ having commercial interest in prescribing 0.727   
Pharmacists' lack of time 0.716   
Potential decrease in quality of current services offered by pharmacists 0.663   
Increased likelihood of litigation 0.662   
Inadequate facilities within pharmacies to allow pharmacist prescribing 0.659   
Conflict of interest with pharmacists acting both as prescribers and dispensers 0.642   
Potential for increased hospital admissions  0.854  
Potential for increased patient costs  0.824  
Potential for increased government costs  0.816  
Potential for a reduction in the quality of patient care  0.731  
Inadequate training in patient diagnosis   0.896 
Inadequate training in patient assessment and monitoring   0.864 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization. Rotation converged in 5 iterations 
 
a factors: i) others; ii) increased cost and deterioration of patient care and iii) inadequate training in 
diagnosis and patient assessment 
 
Table 5 β values for model 2: The relationship between the variables of pharmacist 
prescribing drivers, barriers and pharmacists opinions based upon their experience with 















 Dependent variable: expanding pharmaceutical services through prescribing 

































 Standardized coefficientsa Probability 
 β t 
(Constant) 1.432 6.820 <0.001 
Prescribing drivers 0.747 18.847 <0.001 
Experience with clients 0.127 2.796 0.005 
Diagnosis and Assessment -0.098 -4.094 <0.001 
Cost & deterioration of patient care -0.075 -2.913 0.004 





Other barriers Increased cost, 
deterioration of 
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Fig. 1 Graphical illustration of a relationship model between positive and negative predictors 


















APPENDIX -   QUESTIONNAIRE FOR PHARMACIST PRESCRIBING IN AUSTRALIA 
 
 
The aim of this project is to assess Australian pharmacists’ perceptions on the issue of extended pharmacist prescribing. 
In particular, we are interested in investigating their views on advantages and limitations of such a role as well as areas 
pharmacists feel they should have extended prescribing responsibilities, if any. Pharmacists’ views are being sought on 
what additional training they would require in order to assume future prescribing responsibilities.    
 
This questionnaire consists of statements and questions which enable you to give your opinion on the issue of pharmacist 
prescribing.  It is estimated it will take you approximately 10-15 minutes to complete this questionnaire. Your information 
will be treated with strictest confidence.   
 
To answer this questionnaire please TICK THE BOX NEXT TO THE NUMBER that reflects your opinion 
regarding the statement i.e.:  1 = Strongly disagree; 2 = Disagree; 3 = Neutral; 4 = Agree; 5 = Strongly agree. 




        1)   
 In relation to the way you see the future of the Pharmacy profession, please answer the following:  
 
I would like the Pharmacy profession to expand its scope of professional services 1       2       3       4       5       
I would like the Pharmacy profession to expand its scope of services, by expanding the prescribing role 1       2       3       4       5       
I see myself in future as having more expanded prescribing responsibilities 1       2       3       4       5       
I am happy with the current pharmacist’s prescribing role limited to S3’s 1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
        2) 
Based on your experience with customers in the Pharmacy, please answer the following considering how they would react to 
expanded Pharmacist prescribing:    
 
Customers would accept pharmacists with an expanded prescribing role 1       2       3       4       5       
Customers would trust pharmacists as prescribers 1       2       3       4       5       
Customers would have safer access to their medications if pharmacists were prescribers 1       2       3       4       5       
Customers find accessing  their GP’s too difficult and may prefer Pharmacists having an expanded prescribing role  1       2       3       4       5       
Customers appreciate pharmacist ‘s professional advice and may prefer pharmacists as prescribers 1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
        3) 
In relation to reasons for pharmacist prescribing, please answer the following: 
 
I believe customers would have better access to their medications if pharmacists were prescribers 1       2       3       4       5       
Expanded pharmacist prescribing would ease the burden from overloaded GP’s and hence improve 
the functioning of our health system 
1       2       3       4       5       
Expanded prescribing responsibilities is a direction that the Pharmacy profession should be headed in 
order to secure a more important role in health care 
1       2       3       4       5       
Pharmacists are highly regarded by the community and therefore they should assume more prescribing responsibilities 1       2       3       4       5       
Pharmacists have the necessary drug knowledge to assume more prescribing responsibilities 1       2       3       4       5       
Pharmacists have the necessary patient assessment skills to assume more prescribing responsibilities 1       2       3       4       5       
Pharmacist prescribing enables better use of pharmacist’s professional skills 1       2       3       4       5       
Expanded prescribing will contribute to increased Pharmacy profits 1       2       3       4       5       







          In relation to the way you believe pharmacists should assume expanded prescribing responsibilities, please answer the 
following: 
 
Pharmacists should be able to prescribe independent of medical practitioners, this includes assuming 
the responsibility of clinical assessment of the patient, establishing diagnosis and clinical management 
for a range of conditions within professional and clinical competence. 
1       2       3       4       5       
Pharmacists should be able to prescribe in a supplementary fashion through a partnership with an 
independent prescriber (a doctor or dentist) implementing an agreed patient-specific management 
plan. In this model the doctor diagnoses and initiates therapy while the pharmacist continues 
prescribing as long as patient’s condition is within agreed management plan parameters. 
1       2       3       4       5       
Pharmacists should be able to prescribe from a limited drug formulary which would include current 
S2’s, S3’s and additional drugs depending on pharmacists field of specialization  
1       2       3       4       5       
Pharmacists should be able to prescribe for 30 day emergency supply, rather than current 3 day limit 1       2       3       4       5       
I believe any possible future expanded prescribing should be done by Hospital Pharmacists only 1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
5) 
           For which of the following reasons do you believe pharmacists SHOULD NOT have expanded prescribing rights? 
 
Inadequate training in diagnosis of disease (if this were the pharmacist’s responsibility)  1       2       3       4       5       
Inadequate training in patient assessment and patient monitoring 1       2       3       4       5       
Potential for a reduction in the quality of patient care 1       2       3       4       5       
Potential for increased patient costs 1       2       3       4       5       
Potential for increased hospital admissions 1       2       3       4       5       
Potential for increased government costs 1       2       3       4       5       
Conflict of interest with pharmacists acting both as prescribers and dispensers  1       2       3       4       5       
Pharmacists’ lack of time 1       2       3       4       5       
Increased confusion amongst the public as to the role of GP’s and pharmacists 1       2       3       4       5       
Potential decrease in quality of current services offered by pharmacists 1       2       3       4       5       
Pharmacists having commercial interest in prescribing 1       2       3       4       5       
Inadequate facilities within pharmacies to allow pharmacist prescribing 1       2       3       4       5       
Increased likelihood of litigation 1       2       3       4       5       
None of the above 1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
                       
       a)   Do you think pharmacists should have expanded prescribing rights?              Yes        No      
If answered NO please go to QUESTION 7 
 
       b)   Would you wish to take on an expanded role in prescribing?                             Yes          No      
 
6) 
A) Please answer the question below if you consider that pharmacists should only have an expanded prescribing role in 
partnership with an independent prescriber (e.g. doctor) for any of the following chronic conditions.  
 
Antibiotics (limited number of infections) 1       2       3       4       5       
Diabetes  1       2       3       4       5       
Hypertension  1       2       3       4       5       
Heart failure 1       2       3       4       5       
Asthma and other respiratory conditions 1       2       3       4       5       
Anticoagulant therapies 1       2       3       4       5       
Pain management 1       2       3       4       5       
All of the above 1       2       3       4       5       
                                                                                                                                                       1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
B) Please answer the question below if you consider that pharmacists should have an independent prescribing role for 
any of the following chronic conditions.    
 
Antibiotics (limited number of infections) 1       2       3       4       5       
Diabetes  1       2       3       4       5       
Hypertension  1       2       3       4       5       
Heart failure 1       2       3       4       5       
Asthma and other respiratory conditions 1       2       3       4       5       
Anticoagulant therapies 1       2       3       4       5       
Pain management 1       2       3       4       5       
All of the above 1       2       3       4       5       
 
7)      
                      If I was about to assume additional prescribing responsibilities, I would need further training:        Yes  No   
 
If NO please go straight to question 8.  
 
A)    In order to assume expanded prescribing responsibilities I would need further training in the following therapeutic areas: 
 
Clinical pharmacology 1       2       3       4       5       
Pharmacodynamics and pharmacokinetics 1       2       3       4       5       
Adverse drug reactions and drug interactions 1       2       3       4       5       
Pathophysiology of conditions that you would prescribe for 1       2       3       4       5       
Selection of drug regimen 1       2       3       4       5       
Physiological changes and drug response in different age groups 1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
B)   In order to assume expanded prescribing responsibilities I would need further training in the following areas: 
 
Patient consultation and decision making 1       2       3       4       5       
Communication skills 1       2       3       4       5       
Principles of diagnosis 1       2       3       4       5       
Evidence based practice  1       2       3       4       5       
Legal and ethical aspects of prescribing 1       2       3       4       5       
Psychology of prescribing  1       2       3       4       5       
Principles and methods of patient monitoring (physical examination, laboratory results, patient compliance)  1       2       3       4       5       
Public health issues 1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
C)   In order to assume expanded prescribing responsibilities pharmacist prescribers would need: 
 
A period of supervision by a Medical Practitioner 1       2       3       4       5       
Demonstration of relevant Continuing Education that ensures their prescribing skills are kept to date 1       2       3       4       5       
Specializing in clinical areas that conform with additional prescribing rights assumed (eg. Diabetes, Cardiology, 
Asthma, Anticoagulation, Pain management, Infections) 
1       2       3       4       5       
Specialist registration as presribers with the registering body 1       2       3       4       5       
Other , (please specify):______ 1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 








8)          In relation to the implications of pharmacist prescribing on pharmacy infrastructure: 
 
I believe additional IT resources in the Pharmacy would be needed to support pharmacist prescribing 1       2       3       4       5       
I believe I have access to sufficient patient information  in order  to make prescribing decisions for them 1       2       3       4       5       
I believe prescribing and dispensing should be carried out in separate areas in the Pharmacy  1       2       3       4       5       
I believe a separate quiet consulting area for pharmacist prescribing should be created in the Pharmacy 1       2       3       4       5       
I believe current  staff arrangements in the Pharmacy  can  support  expanded  pharmacist  prescribing 1       2       3       4       5       
I believe independent prescribing  by a pharmacist should NOT occur in a  community pharmacy (excluding S3’s)  1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
9)          In relation to the extension of pharmacists’current roles in the management of minor ailments: 
 
      a) 
I believe a more defined consultation system should be set up for provision of Pharmacist Only 
Medicines (i.e. S3’s)  
1       2       3       4       5       
I believe such a defined consultation system would require a separate consultation room and 
possibility for customers to make appointments with the pharmacist in regards to minor ailments 
1       2       3       4       5       
I believe that any extension of current role in  the management  of  minor ailments would require remuneration 1       2       3       4       5       
I believe medicines prescribed from an expanded role and consultations should be claimable from Medicare  1       2       3       4       5       
I believe current  staff arrangements in the Pharmacy  can  support  an expanded  pharmacist’ s role in the 
management  of  minor ailments 
1       2       3       4       5       
1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree 
 
b) I believe that the time required for such a consultation would have to be: 3 minutes , 5 minutes , 10 minutes  
 
c) I believe that Pharmacist remuneration (excluding medication cost) for such a service would have to be: $_____ per 
consultation (please specify amount)    
 
 
       10)    Please provide us with some further demographics information 
 
• A)Gender: M         F              Age:____years 
• B)How many years have you been registered as a Pharmacist:____years 
• C)Do you own a Pharmacy:  YES                                  NO    
• D)Where do you practice: 
- Western Australia ; NSW  ; VIC ; QLD ; SA ;TAS ; ACT ; NT . 
- Overseas         (Please specify the country:_________________) 
 
• E) Where do you work?   Community           Hospital          Medication Reviews             Other   
• F) Please provide Pharmacy or work location postcode ________ 
• G) If you work in community Pharmacy please indicate its size of operation: small  (turnover < $2m); large  
(turnover >$2 m) 
• H)Telephone contact:______________(OPTIONAL) 
 
Please feel free to contribute to this project by adding your personal comments on important factors for consideration related to 






THANK YOU VERY MUCH FOR YOUR TIME IN PARTICIPATING IN THIS SURVEY 
 Please ensure no answers have been left out as due to the nature of statistical data analysis applied, missing responses can lead to 
exclusion of your valuable information  
